FAACT's Roundtable artwork

Ep. 204: Exciting Updates from AAAAI 2024

FAACT's Roundtable

English - March 02, 2024 17:00 - 29 minutes - 20.1 MB - ★★★★★ - 10 ratings
Medicine Health & Fitness Homepage Download Apple Podcasts Google Podcasts Overcast Castro Pocket Casts RSS feed
Previous Episode: Ep. 203: Mother-Daughter Conversations - What I Wish You Knew
Next Episode: Ep. 205: How Brittany Mahomes Tackles Food Allergies

Learn about ground-breaking news and updates from the recent American Academy of Allergy, Asthma, and Immunology (AAAAI) Annual Meeting held this February in Washington, D.C. In lay relatable terms, FAACT’s Medical Advisory Board Chair, Dr. Shahzad Mustafa, discusses the approval of Xolair and what it means for the food allergy community. He also shares his thoughts regarding treatments that are on-the-horizon for anaphylaxis from ARS Pharma, Bryn Pharma, Aquestive, DBV Technologies, and Blueprint Medicines.

Resources to keep you in the know:

New England Journal of Medicine Publishes Phase III Data Showing Xolair Significantly Reduced Allergic Reactions Across Multiple Foods in People With Food Allergies (Genentech)ARS PharmaBryn PharmaAquestiveDBV TechnologiesBlueprint MedicinesTakeda (EOHILIA)FAACT's Resources:Education Resource CenterDining Out & HandoutTraveling & Traveler's ChecklistBehavioral Health Resource Center

You can also find FAACT’s Roundtable Podcast on Apple Podcast, Spotify, iHeart Radio, Podcast Chaser, Deezer, Tune-In, Alexa, and Listen Notes or wherever you listen to podcasts.

Follow us on Facebook, X (formerly known as Twitter), Instagram, Threads, LinkedIn, Pinterest, TikTok, and

Thanks for listening! FAACT invites you to discover more exciting food allergy resources at FoodAllergyAwareness.org!

Twitter Mentions